Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Machet

Showing results (291-300 of 377) with videos related to

Pageof 38
Sort By:
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patientsMarie Jachiet, Béatrice Flageul, Alban Deroux, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
The British Journal of Dermatology|September 6, 2019
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effectD M Chen, A Odueyungbo, E Csinady, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Pageof 38

Showing results (291-300 of 377) with videos related to

Sort By:
Pageof 38
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patientsMarie Jachiet, Béatrice Flageul, Alban Deroux, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
The British Journal of Dermatology|September 6, 2019
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effectD M Chen, A Odueyungbo, E Csinady, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Pageof 38